Oxford Biomedica (LON:OXB – Get Free Report) had its price target raised by Deutsche Bank Aktiengesellschaft from GBX 250 ($3.35) to GBX 380 ($5.09) in a report issued on Tuesday, LSE.Co.UK reports. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Deutsche Bank Aktiengesellschaft’s price objective would indicate a potential upside of 0.80% from the stock’s current price.
Oxford Biomedica Stock Up 4.7 %
LON:OXB traded up GBX 17 ($0.23) on Tuesday, hitting GBX 377 ($5.05). The stock had a trading volume of 314,716 shares, compared to its average volume of 206,863. The business’s fifty day moving average is GBX 347.48 and its 200 day moving average is GBX 299.34. The company has a market cap of £397.13 million, a PE ratio of -231.29 and a beta of 1.09. The company has a quick ratio of 1.67, a current ratio of 3.19 and a debt-to-equity ratio of 143.20. Oxford Biomedica has a 52 week low of GBX 164.29 ($2.20) and a 52 week high of GBX 394.50 ($5.28).
Oxford Biomedica Company Profile
Recommended Stories
- Five stocks we like better than Oxford Biomedica
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Consumer Discretionary Stocks Explained
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- What is a Low P/E Ratio and What Does it Tell Investors?
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with MarketBeat.com's FREE daily email newsletter.